Patents by Inventor Kun-Ming Rau

Kun-Ming Rau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer specific promoters
    Patent number: 7816131
    Abstract: The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase II? and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: October 19, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Chi-Ping Day, Kun-Ming Rau, Xiaoming Xie, Zheng Li
  • Cancer specific promoters
    Patent number: 7723104
    Abstract: The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase II? and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: May 25, 2010
    Assignee: Board of Regents, The University Of Texas System
    Inventors: Mien-Chie Hung, Chi-Ping Day, Kun-Ming Rau, Xiaoming Xie, Zheng Li
  • CANCER SPECIFIC PROMOTERS
    Publication number: 20080286860
    Abstract: The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase II? and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
    Type: Application
    Filed: January 24, 2007
    Publication date: November 20, 2008
    Inventors: Mien-Chie Hung, Chi-Ping Day, Kun-Ming Rau, Xiaoming Xie, Zheng Li
  • Cancer specific promoters
    Publication number: 20050260643
    Abstract: The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase II? and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
    Type: Application
    Filed: April 1, 2005
    Publication date: November 24, 2005
    Inventors: Mien-Chie Hung, Chi-Ping Day, Kun-Ming Rau, Xiaoming Xie, Zheng Li